| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 450.2 | 424.7 | 386.1 |
| Other income | 5.1 | 8.2 | 7.5 |
| Total income | 455.3 | 432.8 | 393.6 |
| Profit before exceptional items & tax | 77.7 | 69.7 | 61.2 |
| Exceptional items | 0.0 | -0.1 | 0.0 |
| Profit before tax | 77.7 | 69.8 | 61.2 |
| Net profit | 56.9 | 51.0 | 45.2 |
| Operating margin | 17.1% | 16.1% | 15.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +25.90% |
|---|---|
| Net profit, quarter on quarter | +11.60% |
| Revenue, year on year | +16.60% |
| Operating profit, year on year | +35.20% |
| Operating profit, quarter on quarter | +18.00% |
BSE results filing, NSE: METROPOLIS. Figures extracted from the filing.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹582.60
- Market cap
- ₹12,086 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 59.9×Sector 57.8×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Earnings Call Transcript: Key Takeaways
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
- Call
- Guides 15% growth
Metropolis Healthcare Investor Presentation: Key Takeaways
Metropolis Healthcare reports strong Q1FY27 results with Revenue at INR 450 Cr (up 17% YoY) and EBITDA at INR 113 Cr (up 27% YoY).
- Call
- Guides 11% growth
Metropolis Healthcare Earnings Call: Key Takeaways
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.